doi: 10.1097/INF.0b013e31816591f7.
Safety of a fifth dose of diphtheria and tetanus toxoid and acellular pertussis vaccine in children experiencing extensive, local reactions to the fourth dose
Affiliations
- PMID: 18398385
- DOI: 10.1097/INF.0b013e31816591f7
Item in Clipboard
Safety of a fifth dose of diphtheria and tetanus toxoid and acellular pertussis vaccine in children experiencing extensive, local reactions to the fourth dose
Pediatr Infect Dis J.
2008 May.
Abstract
Extensive local reactions have been reported after booster doses of diphtheria and tetanus toxoid and acellular pertussis vaccine, but few data are available on revaccination after these reactions. Of 20 children with extensive local reactions after dose 4, only 4 experienced entire upper arm swelling and 7 had swelling >5 cm after dose 5. These reactions were well tolerated and support revaccination.
Similar articles
-
Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years.Expert Rev Vaccines. 2008 Nov;7(9):1309-20. doi: 10.1586/14760584.7.9.1309. Expert Rev Vaccines. 2008. PMID: 18980534 Review.
-
Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.J Pediatr. 2006 Nov;149(5):603-610. doi: 10.1016/j.jpeds.2006.06.016. J Pediatr. 2006. PMID: 17095328 Clinical Trial.
-
An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.Vaccine. 2007 Jan 22;25(6):1121-5. doi: 10.1016/j.vaccine.2006.09.053. Epub 2006 Oct 2. Vaccine. 2007. PMID: 17045366 Clinical Trial.
-
Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.Vaccine. 2006 Jul 7;24(27-28):5627-36. doi: 10.1016/j.vaccine.2006.04.019. Epub 2006 May 2. Vaccine. 2006. PMID: 16740348 Clinical Trial.
-
Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines.Semin Pediatr Infect Dis. 2003 Jul;14(3):196-8. doi: 10.1016/s1045-1870(03)00033-5. Semin Pediatr Infect Dis. 2003. PMID: 12913831 Review.
Cited by
-
Development of carbohydrate based next-generation anti-pertussis vaccines.Bioorg Med Chem. 2022 Nov 15;74:117066. doi: 10.1016/j.bmc.2022.117066. Epub 2022 Oct 17. Bioorg Med Chem. 2022. PMID: 36283250 Free PMC article. Review.
-
Whole-Cell and Acellular Pertussis Vaccine: Reflections on Efficacy.Med Princ Pract. 2022;31(4):313-321. doi: 10.1159/000525468. Epub 2022 Jun 13. Med Princ Pract. 2022. PMID: 35696990 Free PMC article. Review.
-
Roads to the development of improved pertussis vaccines paved by immunology.Pathog Dis. 2015 Nov;73(8):ftv067. doi: 10.1093/femspd/ftv067. Epub 2015 Sep 6. Pathog Dis. 2015. PMID: 26347400 Free PMC article. Review.
-
Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine.PLoS Pathog. 2013;9(4):e1003264. doi: 10.1371/journal.ppat.1003264. Epub 2013 Apr 4. PLoS Pathog. 2013. PMID: 23592988 Free PMC article.
-
Comprehensive assessment of serious adverse events following immunization by health care providers.J Pediatr. 2013 Jun;162(6):1276-81, 1281.e1. doi: 10.1016/j.jpeds.2013.01.028. Epub 2013 Feb 26. J Pediatr. 2013. PMID: 23452584 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
